Kazimierczak et al., (2020) discovered a new biological marker for monitoring melanoma immunotherapy, where there is a positive correlation between the production of antibodies to BNIP3L/NIX and the clinical outcome of melanoma patients treated with the AGI-101H vaccine [55]. This evidence concerns the gene BNIP3L and melanoma.